Chai brews up $400M series C to fuel AI molecule models used by Lilly, Novartis and Pfizer
Summary
Chai raised $400 million in a Series C round to expand its AI molecule modeling business. The company’s software is already used by major pharmaceutical companies including Lilly, Novartis, and Pfizer. The funding should help Chai scale its platform and deepen its capabilities for drug discovery and molecular design. The headline signals continued investor confidence in AI tools for life sciences.
Funding
Amount
$400.0M
Total raised
Date
July 14, 2026
Announcement date
Investors
Pfizer Venture Capital, Novartis Venture Fund, Eli Lilly and
Lead investors
Company
chaidiscovery.com
Funded company
Classifications
industries
No industries detected
applications
Software Design & Development
AskAI Classifications
Labels
Software Development
Blockchain Software
Web3 Technology
Linked Companies
Edenia
$1M to $5M